Recent Finacing
Recent Raise
Aeglea Biotherapeutics engineers human enzymes to degrade specific amino acids for enzyme-replacement therapies and systemic amino-acid–depleting cancer treatments, with a lead arginase candidate and preclinical programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors